Clinical trials
Advanced Gastric Cancer clinical trials
Below are recruiting advanced gastric cancer clinical trials, each written for real people, not researchers. We’re tracking 410 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Little Rock, ArkansasAges 19 years+ - NCT07789184RecruitingPhase 3
Surgery versus no surgery after successful conversion therapy for stomach cancer with peritoneal spread
This trial compares having surgery to remove stomach cancer versus not having surgery in patients whose cancer in the abdominal lining responded well to initial treatment. The goal is to see which approach helps patients live longer and feel better.
Beijing, Beijing MunicipalityAges 18–70 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+ - NCT03961373RecruitingPhase 3
Standard vs longer lymph node surgery after chemo for stomach cancer
This study compares two surgical approaches to remove lymph nodes after you’ve already had chemotherapy for stomach cancer. It aims to see whether removing lymph nodes in a more extended way improves outcomes without causing unacceptable side effects.
SienaAges 18–80 - NCT03825861RecruitingPhase 2
Before-surgery chemotherapy for locally advanced stomach cancer
This Phase 2 study tests chemotherapy given before surgery (called FOLFIRINOX) for people with locally advanced stomach cancer. The goal is to shrink the tumor and improve outcomes after the surgery plan is completed.
São PauloAges 18–75 - NCT04843215Recruiting
Surgery comparison for advanced stomach cancer after initial surgery
This trial studies whether removing all of the fatty lining (omentum) or only part of it during surgery leads to better outcomes in people with advanced stomach cancer. It also checks that participants can safely have the same stomach-cancer chemotherapy plan after surgery.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT06028724Recruiting
Looking for cancer mutations using a blood test
This study uses a blood test (liquid biopsy) to find genetic changes in advanced solid tumors. It may help doctors choose the right treatment and monitor how well it works over time.
Aviano, PordononeAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06102772Recruiting
Combination immunotherapy and targeted therapy for advanced gastric cancer
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102785Recruiting
Fruquintinib plus TAS102 for advanced stomach cancer
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06102759Recruiting
Study of adebrelimab and fruquintinib plus chemo for advanced stomach cancer after PD-1 failure
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT05140746Recruiting
Predicting how well chemotherapy works before stomach surgery
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07855640Recruiting
Immunotherapy plus chemo for advanced stomach cancer with fluid in belly
This trial tests a new combination for advanced stomach cancer that has spread and caused fluid buildup in the belly (malignant ascites). It combines an immunotherapy drug (anti-PD-1) with standard chemotherapy and a targeted chemotherapy given directly into the belly to see if it can shrink the cancer and help you feel better.
Hangzhou, ZhejiangAges 18–75 - NCT01935778RecruitingPhase 3
Extra chemo after stomach cancer surgery: compare two drug plans
This Phase 3 trial tests which combination of chemotherapy works better after surgery for stage IIIB/IV stomach or stomach–esophagus junction adenocarcinoma. Participants get randomized to one of two chemotherapy plans to see which helps people live longer and/or prevents cancer from coming back.
SeoulAges 20–75 - NCT06177041RecruitingPhase 3
M108 plus chemo for CLDN18.2-positive stomach cancer
This trial tests a new drug (M108) combined with standard chemotherapy (CAPOX) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has a specific protein called Claudin 18.2. The goal is to see if adding M108 helps improve outcomes compared to chemotherapy alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT04597294RecruitingPhase 3
Preventive pre-op HIPEC for advanced stomach cancer
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
Krakow, Lesser Poland VoivodshipAges 18–75 - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Birmingham, AlabamaAges 18 years+ - NCT06341595RecruitingPhase 2
Chemo, radiation and immunotherapy before surgery for stomach cancer with PALM
This trial tests combining chemotherapy, radiation, and an immunotherapy drug (sintilimab) before surgery for advanced stomach cancer that has spread to lymph nodes near the aorta (called PALM). The goal is to see if this approach can shrink the tumor enough to allow complete removal.
Nanjing, JiangsuAges 18–75 - NCT05699655RecruitingPhase 2/Phase 3
New pre-surgery treatment for advanced stomach cancer with immunotherapy
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Fuzhou, FujianAges 18–75 - NCT04891016RecruitingPhase 2
Immunotherapy with chemotherapy for locally advanced stomach cancer
This trial studies toripalimab (an immune system medicine) plus FLOT chemotherapy in people with stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to improve control of the cancer and help more people have their tumors fully treated.
Zhengzhou, HenanAges 18–70 - NCT05187338RecruitingPhase 1/Phase 2
Study drugs that target immune checkpoints for solid tumors
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Guangzhou, GuangdongAges 18–70
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced gastric cancer?
- Yes. Clin2 currently lists 410 recruiting advanced gastric cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced gastric cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced gastric cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.